{"status":"success","data":{"title":"Supratherapeutic INR","slug":"supratherapeutic-inr","tags":["coumadin","vitamin K","PCC","FFP","aspirin","clopidogrel,"],"collection":["Hematology and Oncology"],"content":"<h1 id=\"overanticoagulation-and-supratherapeutic-inr\">Overanticoagulation and Supratherapeutic INR</h1>\n<p><strong>ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)</strong></p>\n<table>\n<thead>\n<tr>\n<th><strong>INR</strong></th>\n<th><strong>Therapeutic intervention</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>â‰¤ 10</td>\n<td><em>If no bleeding:</em> Hold <span class=\"drug\">coumadin</span>. Restart when INR is therapeutic</td>\n</tr>\n<tr>\n<td>&gt; 10</td>\n<td><em>If no bleeding</em>: Hold <span class=\"drug\">coumadin</span>. Give oral <span class=\"drug\">vitamin K</span> (2.5 mg)</td>\n</tr>\n<tr>\n<td>Major bleed</td>\n<td>Hold <span class=\"drug\">coumadin</span>. Give <span class=\"drug\">vitamin K</span> (5-10 mg slow IVP), 4-factor <span class=\"drug\">PCC</span> (<span class=\"drug\">FFP</span> not of added benefit with <span class=\"drug\">PCC</span>)</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Higher bleeding risk associated with coumadin</strong></p>\n<ul>\n<li><em>NSAIDS:</em> non-selective and COX-2 selective</li>\n<li><em>Antiplatelet agents</em>: <span class=\"drug\">aspirin</span>, <span class=\"drug\">clopidogrel</span></li>\n<li><strong><em>Clotrimoxazole</em></strong></li>\n<li><em>Antibiotics</em> (especially fluoroquinolones)</li>\n</ul>\n<p><strong>Pearl</strong></p>\n<ul>\n<li>Risk of intracranial hemorrhage doubles for every 1-point increase in INR</li>\n</ul>\n<h2 id=\"causes-for-supratherapeutic-inr-gt-6\">Causes for supratherapeutic INR &gt; 6</h2>\n<p><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/9496982\">Hylek et al. JAMA 1998 study</a></p>\n<ul>\n<li>Retrospective case-control study of patients with INR &gt; 6</li>\n<li>Enrolled 93 cases, 196 controls</li>\n</ul>\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th><strong>Risk factor/explanation</strong></th>\n<th><strong>OR</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td>Advanced malignancy</td>\n<td>16.4</td>\n</tr>\n<tr class=\"even\">\n<td><strong></strong>\n<p><span class=\"drug\">Acetaminophen</span> intake  4.5-9.1 g/wk<br />\n  &gt; 9.1 g/wk</p></td>\n<td><br />\n6.8<br />\n10</td>\n</tr>\n<tr class=\"odd\">\n<td>New medication</td>\n<td>8.5</td>\n</tr>\n<tr class=\"even\">\n<td>Excess <span class=\"drug\">coumadin</span> intake</td>\n<td>8.1</td>\n</tr>\n<tr class=\"odd\">\n<td>Decreased oral intake</td>\n<td>3.6</td>\n</tr>\n<tr class=\"even\">\n<td>Acute diarrheal illness</td>\n<td>3.5</td>\n</tr>\n<tr class=\"odd\">\n<td>Vitamin K intake</td>\n<td>0.7</td>\n</tr>\n<tr class=\"even\">\n<td>Alcohol use<br />\n(1 drink QOD-2 drinks daily)</td>\n<td>0.2</td>\n</tr>\n</tbody>\n</table>\n\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/9496982\">Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62</a></li>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22315259\">Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295.</a></li>\n</ul>\n"}}